Mineralys Therapeutics, Inc.
MLYS
$25.02
-$0.71-2.76%
NASDAQ
Corporate Info
Website
Phone Number
888 378 6240
Address
150 N. Radnor Chester Road
Suite F200
Radnor, PA 19087
Suite F200
Radnor, PA 19087
Country
United States
Year Founded
2019
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
76
Business Description
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.